Board
Screen
Heat
Cal
Watch
News
Blog
TV
News

Can Argan Keep Its Earnings Streak Alive as Backlog Slips Further?

Argan (AGX) posted 61.5% revenue growth with expanding margins, supported by strong power demand and $1.03 billion in liquidity. However, the company's backlog slipped further…
Nov 5, 11:31 AM ·

AI in Ophthalmology Market Size, Share, and Trends Analysis 2026-2036: Evaluates AI Adoption Across Ophthalmic Imaging, Diagnostics, Surgical Planning, and Clinical Workflows

ResearchAndMarkets.com has added a global AI in ophthalmology market report covering 2026-2036, estimating the market at USD 430 (unit unspecified in the excerpt). The forecast…
Nov 5, 11:30 AM

Brunswick annonce une augmentation de la taille de son placement sous le régime de la dispense pour financement de l’émetteur coté et son placement privé simultané annoncés précédemment pour un produit brut pouvant atteindre 20 million $

Brunswick Exploration (TSX-V: BRW) increased its previously announced marketed private placement to gross proceeds of up to C$17.84 million, citing strong investor demand, with…
Nov 5, 11:30 AM ·

Repligen: 3 Key Takeaways for Long-Term Investors

Repligen (RGEN) reported third-quarter revenue of $209 million. The company expects its BioLife unit to contribute $24 million in fourth-quarter revenue.
Nov 5, 11:30 AM ·

IQIRVO® late-breaking data raises ambitions in PBC with more than 85% of patients on treatment achieving ALP normalization

Late-breaking ELSPIRE data presented at The Liver Meeting 2026 and published in HEPATOLOGY show 85.3% of IQIRVO-treated patients achieved ALP normalization at Week 52 in primary…
Nov 5, 11:30 AM

Here's the 1 Stock I'd Most Want to Buy If the Market Crashes

Viking Therapeutics (VKTX) is highlighted as a stock to watch, with its ongoing phase 3 trials for lead drug VK2735 cited as the key catalyst for shareholder value. The article…
Nov 5, 11:30 AM ·

Pluxee convenes its Fiscal 2026 Annual General Meeting of Shareholders

Pluxee has published the agenda and explanatory notes for its Fiscal 2026 Annual General Meeting of Shareholders, scheduled for December 17, 2026 at 2:00 pm CET in…
Nov 5, 11:30 AM

Les données «late-breaking» sur IQIRVO® relèvent les ambitions thérapeutiques dans la CBP : plus de 85 % des patients traités obtiennent une normalisation des PAL

Ipsen (Euronext: IPN; ADR: IPSEY) reported late-breaking Phase III ELSPIRE data showing IQIRVO achieved alkaline phosphatase (ALP) normalization in 85.3% of patients at week 52…
Nov 5, 11:30 AM

Pluxee convoque son Assemblée générale annuelle d’actionnaires pour l’exercice 2026

Pluxee has published the agenda and explanatory notes for its 2026 annual general meeting of shareholders, scheduled for December 17, 2026 at 14:00 CET in Amsterdam-Schiphol…
Nov 5, 11:30 AM

COURTOIS SA : Variation droits de vote 10/2026

Courtois SA (FR0000065393) published its voting-rights breakdown as of October 31, 2026, dated November 5, 2026. The filing restates Article 10 of the company's bylaws, which…
Nov 5, 11:30 AM
Repligen: 3 Key Takeaways for Long-Term Investors
Nov 5, 11:30 AM·
Medium Neutral

Sources

Summarized by i88

Tickers

Summary

Repligen (RGEN) reported third-quarter revenue of $209 million. The company expects its BioLife unit to contribute $24 million in fourth-quarter revenue.

Repligen Reports $209 Million in Third-Quarter Revenue

Repligen (RGEN) reported revenue of $209 million in the third quarter, according to an earnings takeaways article published by fool.com on November 5, 2026.

BioLife Outlook

The company expects its BioLife unit to contribute $24 million in fourth-quarter revenue.

Key Figures at a Glance

  • Third-quarter revenue: $209 million
  • Expected fourth-quarter BioLife revenue: $24 million

The source material did not provide additional details on profitability, guidance for other business segments, or comparisons with prior periods.